Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. We envision a world where all women and their babies have access to safe and effective therapies for treating life threatening complications of pregnancy, and those solutions must be evidence-based and affordable.
Cerevance LLC is engaged in the development of therapeutics targeting specific proteins expressed selectively in brain cell types affected by neurological diseases. The company utilizes its proprietary NETSseq platform to profile distinct brain cell types, such as neurons and glial cells, in mature human brain tissue. This technology reveals transcriptional and epigenetic differences, facilitating the early detection and treatment of serious neurological and psychiatric disorders, including Alzheimer’s and Parkinson’s diseases. Founded in 2016, Cerevance is headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom. The company's focus is on advancing new medicines for central nervous system diseases by addressing the underlying mechanisms of neurodegeneration and related conditions.
Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to create innovative treatments that address the underlying causes of mitochondrial issues. By leveraging a comprehensive understanding of mitochondrial mechanisms, Pretzel Therapeutics seeks to reverse dysfunction at its roots, potentially providing effective solutions for patients suffering from a range of conditions, including those related to aging. The company's name reflects its scientific focus on the mitochondrion, which is characterized by its unique and highly folded inner membrane, distinguishing it from other organelles in the body.
Fractyl Health Inc. is a medical device company specializing in innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company's flagship product, Revita DMR, is a minimally invasive procedure that utilizes hydrothermal ablation to rejuvenate the lining of the duodenum, effectively addressing the underlying causes of these conditions. By focusing on transforming the treatment of metabolic diseases from merely managing symptoms to providing durable, disease-modifying solutions, Fractyl Health aims to significantly improve patient health outcomes. Founded in 2010 and based in Lexington, Massachusetts, the company is committed to developing curative therapies that lessen the burden on patients, healthcare providers, and payers.
Merlin Labs is building an autonomous infrastructure for the sky above us, enabling goods, and eventually people, to fly without pilots.
SingleStore, Inc. is a provider of relational databases designed for both cloud and on-premises transactions and analytics. The company offers the SingleStore Managed Service, a cloud database-as-a-service that facilitates analytics on various cloud platforms, as well as SingleStore DB, a distributed SQL database suitable for operational analytics on bare metal and hybrid cloud environments. SingleStore's solutions include modernizing data platforms, securing government workloads, IoT analytics, and customer interaction management, serving diverse sectors such as financial services, media, energy, government, and retail. Founded in 2011 and headquartered in San Francisco, California, SingleStore also has offices in Seattle, Boston, Portland, Lisbon, and London. Previously known as MemSQL Inc., the company rebranded to SingleStore, Inc. in October 2020.
FYTO provides innovative solutions which improve the economic and environmental sustainability of agriculture for farmers around the world. FYTO is developing:
NOVEL NUTRIENT-DENSE CROPS that have ultra-high yields and ultra-low resource requirements, STATE-OF-THE ART CULTIVATION AND HARVESTING SYSTEMS for exceptional quality and consistency, CLIMATE-FRIENDLY METHODOLOGIES for resiliency and long-term sustainability, and a range of GROUNDBREAKING AGRICULTURAL PRODUCTS such as animal feed and biofertilizer.
Courier provides an API that enables developers to manage and route user notifications across various communication channels, such as email and messaging platforms. By leveraging user engagement data and online status, the API optimizes notification delivery, ensuring that messages reach users through the most effective medium. The company's notification management software allows clients to create reusable messages that can be customized for different channels, facilitating timely and targeted communication. Over the years, Courier has adapted to technological advancements while maintaining a stable management approach, emphasizing the importance of customer success. The company has developed long-lasting relationships with its largest clients, continually collaborating to meet their evolving needs.
Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.
Celsius Therapeutics is a biotechnology company focused on developing innovative medicines to treat complex diseases, including autoimmunity and cancer. Founded in 2017 and based in Cambridge, Massachusetts, the company leverages advanced techniques such as single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. By systematically applying single-cell sequencing and analyzing extensive datasets with sophisticated algorithms, Celsius Therapeutics aims to discover critical biomarkers and precision therapies that enhance patient care and enable clinicians to identify genes that play a causal role in various conditions.
LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated, genomically-enabled drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine aims to elucidate human biology and develop innovative therapeutics that target the underlying causes of serious diseases. By mining fungal biodiversity, the company seeks to create novel therapeutics designed to tackle previously intractable medical challenges, ultimately enhancing treatment options for healthcare providers.
RightHand Robotics, Inc. specializes in manufacturing robotic order-picking systems designed for various industrial applications, including e-commerce, food handling, and flexible manufacturing. The company offers innovative products such as the ReFlex SF, which features a 3D-printed palm equipped with servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor that enhances the robots' ability to grasp items gently and make adjustments to avoid errors. Their technology allows robots to automatically grasp a wide range of items from bins and cases, eliminating the need for extensive data-entry or parameter-tuning, thereby making the systems cost-effective and adaptable to the evolving needs of businesses. Founded in 2015, RightHand Robotics is headquartered in Cambridge, Massachusetts, with a sales and business development office located in Frankfurt, Germany.
Ventus Therapeutics U.S., Inc. is a biopharmaceutical company based in Natick, Massachusetts, with an additional location in Montreal, Canada. Founded in 2019, it focuses on discovering and developing novel small-molecule medicines that target the innate immune system to address autoimmune diseases, inflammatory diseases, and cancer. The company employs a structural immunology platform that integrates protein engineering to elucidate molecular structures and mechanisms of action. This platform facilitates the development of precise binding and functional screening assays, as well as structure-based modeling. Ventus Therapeutics is advancing an emerging pipeline of drug programs aimed at key targets within the innate immune system, leveraging its proprietary capabilities in rational and structure-based drug design.
Seismic Therapeutic is a biotechnology company focused on accelerating immunology drug development through the integration of machine learning in the biologics discovery process. Utilizing its IMPACT™ platform, Seismic Therapeutic aims to tackle key challenges in biologics discovery by combining structural biology, protein engineering, and translational immunology. This comprehensive approach facilitates the creation of optimized therapies that can reach patients more quickly. The company is developing a pipeline of innovative biologics targeting adaptive immune system dysregulation, with the goal of treating autoimmune diseases.
Scandit AG, established in 2009 and headquartered in Zurich, Switzerland, specializes in mobile computer vision and augmented reality solutions, focusing on barcode scanning software. Its offerings include the Scandit Keyboard Wedge, which enables enterprise-grade barcode scanning on mobile devices, and the Barcode Scanner SDK, which allows for barcode scanning integration in web applications. The MatrixScan technology enhances the speed of barcode and text recognition, making it valuable for industries such as retail, logistics, manufacturing, healthcare, and government. Scandit's solutions are designed to improve operational efficiency by enabling mobile shopping, self-checkout, inventory management, and asset tracking, while also facilitating patient and medication tracking in healthcare settings. The company serves a diverse clientele, including well-known organizations like 7-Eleven, Carrefour, and Toyota, among others, and has additional offices in San Francisco, Boston, London, and Warsaw.
Cockroach Labs, Inc. specializes in developing open-source database software, notably CockroachDB, which is a distributed SQL database tailored for modern cloud applications. Founded in 2015 and headquartered in New York, the company also has an office in Cambridge, Massachusetts. CockroachDB is designed to scale horizontally and can withstand various types of failures, including those at the disk, machine, rack, and datacenter levels, while maintaining minimal latency and no need for manual intervention. It supports strongly-consistent ACID transactions and offers an SQL API for data management. The software is suitable for diverse clients, ranging from startups to Fortune 500 companies, and is utilized for enterprise-grade disaster recovery services. CockroachDB combines the rich features of SQL with the scalability typically associated with NoSQL databases, enabling developers to innovate rapidly without compromising on consistency. The platform is trusted by major enterprises across various sectors, including finance, retail, and media.
Mabl Inc. offers an automated testing service that leverages machine learning to identify regressions and automatically fix broken tests. Founded in 2016 and based in Boston, Massachusetts, the company provides a scriptless testing solution as part of its software-as-a-service (SaaS) offerings. Mabl facilitates machine-driven regression testing and integrates seamlessly into the continuous integration and continuous delivery (CI/CD) development lifecycle. Its platform allows software development teams to create, execute, and maintain auto-healing tests efficiently, ensuring the rapid delivery of high-quality applications. Mabl serves a range of enterprise clients, including Johnson Controls, Liberty Mutual, Molina Healthcare, JetBlue, Dollar Shave Club, and Charles Schwab, who rely on its services for testing their critical applications.
Provider of cancer therapy services intended to improve both the safety and efficacy of cytokine immunotherapies for cancer patients. The company's services offer systemic dosing of these immune stimulants that have historically been limited by broad immune activation and toxicity, develops cancer therapies based on tumor-localized immune potentiating agents that boost anti-tumor immune responses, enabling patients to find an instant treatment for cancer without any surgery.
RightHand Robotics, Inc. specializes in manufacturing robotic order-picking systems designed for various industrial applications, including e-commerce, food handling, and flexible manufacturing. The company offers innovative products such as the ReFlex SF, which features a 3D-printed palm equipped with servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor that enhances the robots' ability to grasp items gently and make adjustments to avoid errors. Their technology allows robots to automatically grasp a wide range of items from bins and cases, eliminating the need for extensive data-entry or parameter-tuning, thereby making the systems cost-effective and adaptable to the evolving needs of businesses. Founded in 2015, RightHand Robotics is headquartered in Cambridge, Massachusetts, with a sales and business development office located in Frankfurt, Germany.
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, ROME Therapeutics is pioneering the exploration of the repeatome, which consists of extensive regions of genetic material previously considered "junk DNA." The company has identified several drug targets and is actively advancing multiple discovery programs. To facilitate its research, ROME has assembled a team of experts across various disciplines, including oncology, immunology, virology, and machine learning, to harness this uncharted area of biology for therapeutic advancements.
SingleStore, Inc. is a provider of relational databases designed for both cloud and on-premises transactions and analytics. The company offers the SingleStore Managed Service, a cloud database-as-a-service that facilitates analytics on various cloud platforms, as well as SingleStore DB, a distributed SQL database suitable for operational analytics on bare metal and hybrid cloud environments. SingleStore's solutions include modernizing data platforms, securing government workloads, IoT analytics, and customer interaction management, serving diverse sectors such as financial services, media, energy, government, and retail. Founded in 2011 and headquartered in San Francisco, California, SingleStore also has offices in Seattle, Boston, Portland, Lisbon, and London. Previously known as MemSQL Inc., the company rebranded to SingleStore, Inc. in October 2020.
Nym Health Inc. specializes in developing advanced medical coding technology aimed at enhancing revenue cycle processes within healthcare facilities. Its flagship product, Nym, offers a direct-to-billing autonomous coding solution that significantly reduces claims denials and operational costs while accelerating payment cycles and ensuring audit-readiness. The platform automatically identifies and captures relevant clinical information from patient charts, assigning codes only to fully understood cases; unhandled charts are sent back for human coding. Additionally, Nym provides a detailed audit-trail view that explains the rationale behind each coding decision, facilitating quick comprehension for validation, compliance, and appeals purposes. Founded in 2017 and headquartered in Boston, Massachusetts, the company also maintains a research and development center in Tel Aviv-Yafo, Israel.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
Merlin Labs is building an autonomous infrastructure for the sky above us, enabling goods, and eventually people, to fly without pilots.
Dyno Therapeutics Inc. specializes in the development of adeno-associated virus (AAV) vectors for in vivo delivery of gene therapies. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes an artificial intelligence-driven approach that integrates DNA synthesis, sequencing, and machine learning. This innovative methodology enables the design of novel gene vectors with an emphasis on cell-targeting capsid proteins derived from AAV, which is recognized as the most commonly used vector in gene therapy applications. By leveraging quantitative high-throughput in vivo experimentation, Dyno Therapeutics aims to enhance the effectiveness and precision of gene therapy solutions.
Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.
Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, CT.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
Ventus Therapeutics U.S., Inc. is a biopharmaceutical company based in Natick, Massachusetts, with an additional location in Montreal, Canada. Founded in 2019, it focuses on discovering and developing novel small-molecule medicines that target the innate immune system to address autoimmune diseases, inflammatory diseases, and cancer. The company employs a structural immunology platform that integrates protein engineering to elucidate molecular structures and mechanisms of action. This platform facilitates the development of precise binding and functional screening assays, as well as structure-based modeling. Ventus Therapeutics is advancing an emerging pipeline of drug programs aimed at key targets within the innate immune system, leveraging its proprietary capabilities in rational and structure-based drug design.
Lightmatter, Inc. is an artificial intelligence (AI) hardware company based in Boston, Massachusetts, that specializes in integrated optical technology to develop advanced computing processors. Founded in 2017, the company has created a silicon chip that utilizes light signals for processing, offering a new approach to AI computation. This technology accelerates critical operations in deep neural networks by employing programmable photonic elements alongside traditional transistors, enhancing the speed and efficiency of data processing while minimizing power consumption. Lightmatter's innovations aim to improve various AI applications, including image recognition and natural language processing, contributing to the advancement of next-generation AI-powered computing solutions.
Snyk Ltd. is a developer-focused cybersecurity company that provides a software-as-a-service platform designed to help organizations identify, fix, and monitor vulnerabilities in open-source dependencies and container images. The platform includes tools such as Snyk Code, which offers static application security testing, and container vulnerability management, which addresses vulnerabilities in Docker images. Snyk enables developers to scan their code for security issues directly within their code editors, providing alerts and remediation guidance based on an internal database of known vulnerabilities. The company also offers features for application security management, licensing compliance, and infrastructure as code security. Founded in 2015 and headquartered in London, Snyk has additional offices in Tel Aviv, Boston, and Ontario, and has established a strategic partnership with Rapid7, Inc.
Hyperfine Research Inc. specializes in developing portable magnetic resonance imaging (MRI) scanners, aimed at making medical imaging more accessible. Founded in 2014 and based in Guilford, Connecticut, the company focuses on general anatomical brain imaging and addresses various medical conditions, including headaches, strokes, non-specific muscle weakness, encephalopathy, spinal cord compressions, diabetic foot disease, and musculoskeletal trauma. Within a year of its establishment, Hyperfine successfully produced its first images, and it has since improved the quality and functionality of its imaging technology. The company’s mission is to democratize healthcare by ensuring that medical imaging is available to people worldwide.
Hyperfine Research Inc. specializes in developing portable magnetic resonance imaging (MRI) scanners, aimed at making medical imaging more accessible. Founded in 2014 and based in Guilford, Connecticut, the company focuses on general anatomical brain imaging and addresses various medical conditions, including headaches, strokes, non-specific muscle weakness, encephalopathy, spinal cord compressions, diabetic foot disease, and musculoskeletal trauma. Within a year of its establishment, Hyperfine successfully produced its first images, and it has since improved the quality and functionality of its imaging technology. The company’s mission is to democratize healthcare by ensuring that medical imaging is available to people worldwide.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.
Cockroach Labs, Inc. specializes in developing open-source database software, notably CockroachDB, which is a distributed SQL database tailored for modern cloud applications. Founded in 2015 and headquartered in New York, the company also has an office in Cambridge, Massachusetts. CockroachDB is designed to scale horizontally and can withstand various types of failures, including those at the disk, machine, rack, and datacenter levels, while maintaining minimal latency and no need for manual intervention. It supports strongly-consistent ACID transactions and offers an SQL API for data management. The software is suitable for diverse clients, ranging from startups to Fortune 500 companies, and is utilized for enterprise-grade disaster recovery services. CockroachDB combines the rich features of SQL with the scalability typically associated with NoSQL databases, enabling developers to innovate rapidly without compromising on consistency. The platform is trusted by major enterprises across various sectors, including finance, retail, and media.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated, genomically-enabled drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine aims to elucidate human biology and develop innovative therapeutics that target the underlying causes of serious diseases. By mining fungal biodiversity, the company seeks to create novel therapeutics designed to tackle previously intractable medical challenges, ultimately enhancing treatment options for healthcare providers.
FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.
SingleStore, Inc. is a provider of relational databases designed for both cloud and on-premises transactions and analytics. The company offers the SingleStore Managed Service, a cloud database-as-a-service that facilitates analytics on various cloud platforms, as well as SingleStore DB, a distributed SQL database suitable for operational analytics on bare metal and hybrid cloud environments. SingleStore's solutions include modernizing data platforms, securing government workloads, IoT analytics, and customer interaction management, serving diverse sectors such as financial services, media, energy, government, and retail. Founded in 2011 and headquartered in San Francisco, California, SingleStore also has offices in Seattle, Boston, Portland, Lisbon, and London. Previously known as MemSQL Inc., the company rebranded to SingleStore, Inc. in October 2020.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing therapies aimed at protecting, repairing, and restoring hearing. The company focuses on a range of hearing disorders, including those related to cancer treatments, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as tinnitus. It utilizes advanced techniques such as single-cell genomics, bioinformatics, and precision gene therapy technologies to enhance its understanding of inner ear pathology and to develop effective treatments. Decibel Therapeutics also offers expertise in drug delivery to the inner ear, imaging, and pharmacokinetic modeling, contributing to innovative therapeutic approaches for patients experiencing various forms of hearing loss. Founded in 2013 and based in Boston, Massachusetts, Decibel Therapeutics was previously known as Hearing, Inc. before rebranding in 2014.
Superplastic, Inc. is a character-based product and entertainment company founded in 2017 and based in Burlington, Vermont. The company specializes in manufacturing and marketing limited edition art toys, apparel, games, and animation, featuring unique characters created in collaboration with renowned artists. Superplastic leverages the principles of effort and scarcity to enhance the value of its offerings, creating exclusive works of art for a select audience. The company also operates a platform that engages customers through various media, including animated videos and music, enabling interactions with its synthetic superstars in innovative ways. Products are primarily sold online, reflecting a modern approach to retail and entertainment.
Nym Health Inc. specializes in developing advanced medical coding technology aimed at enhancing revenue cycle processes within healthcare facilities. Its flagship product, Nym, offers a direct-to-billing autonomous coding solution that significantly reduces claims denials and operational costs while accelerating payment cycles and ensuring audit-readiness. The platform automatically identifies and captures relevant clinical information from patient charts, assigning codes only to fully understood cases; unhandled charts are sent back for human coding. Additionally, Nym provides a detailed audit-trail view that explains the rationale behind each coding decision, facilitating quick comprehension for validation, compliance, and appeals purposes. Founded in 2017 and headquartered in Boston, Massachusetts, the company also maintains a research and development center in Tel Aviv-Yafo, Israel.
Fractyl Health Inc. is a medical device company specializing in innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company's flagship product, Revita DMR, is a minimally invasive procedure that utilizes hydrothermal ablation to rejuvenate the lining of the duodenum, effectively addressing the underlying causes of these conditions. By focusing on transforming the treatment of metabolic diseases from merely managing symptoms to providing durable, disease-modifying solutions, Fractyl Health aims to significantly improve patient health outcomes. Founded in 2010 and based in Lexington, Massachusetts, the company is committed to developing curative therapies that lessen the burden on patients, healthcare providers, and payers.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.
PatientPing, Inc. operates a national care coordination network designed to connect healthcare providers through real-time notifications when patients receive care. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers technology solutions for various healthcare stakeholders, including Accountable Care Organizations, hospitals, payers, and post-acute care facilities. Its network comprises a range of healthcare professionals, such as emergency case managers, primary care physicians, and care coordinators, facilitating improved collaboration and information sharing. PatientPing also features a tool called Spotlights, which analyzes real-time data to identify trends in healthcare utilization and performance. The company has formed a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC, focusing on enhancing patient outcomes and experiences through coordinated care.
Scandit AG, established in 2009 and headquartered in Zurich, Switzerland, specializes in mobile computer vision and augmented reality solutions, focusing on barcode scanning software. Its offerings include the Scandit Keyboard Wedge, which enables enterprise-grade barcode scanning on mobile devices, and the Barcode Scanner SDK, which allows for barcode scanning integration in web applications. The MatrixScan technology enhances the speed of barcode and text recognition, making it valuable for industries such as retail, logistics, manufacturing, healthcare, and government. Scandit's solutions are designed to improve operational efficiency by enabling mobile shopping, self-checkout, inventory management, and asset tracking, while also facilitating patient and medication tracking in healthcare settings. The company serves a diverse clientele, including well-known organizations like 7-Eleven, Carrefour, and Toyota, among others, and has additional offices in San Francisco, Boston, London, and Warsaw.
SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.
scPharmaceticals is creating innovative and important new therapeutic options by administering drugs subcutaneously using a convenient two component delivery system suitable for patient self-administration.In February 2013 scPharmaceuticals was formed to continue the groundbreaking work of SpringLeaf Therapeutics, a Boston area company that started in 2007. scPharmaceuticals targets the untapped opportunity of treating patients with serious medical conditions with a convenient safe and comfortable subcutaneous administration of a drug. This is therapeutically equivalent to intravenous administration while avoiding the cost, burden and risks associated with intravenous administration.
Ventus Therapeutics U.S., Inc. is a biopharmaceutical company based in Natick, Massachusetts, with an additional location in Montreal, Canada. Founded in 2019, it focuses on discovering and developing novel small-molecule medicines that target the innate immune system to address autoimmune diseases, inflammatory diseases, and cancer. The company employs a structural immunology platform that integrates protein engineering to elucidate molecular structures and mechanisms of action. This platform facilitates the development of precise binding and functional screening assays, as well as structure-based modeling. Ventus Therapeutics is advancing an emerging pipeline of drug programs aimed at key targets within the innate immune system, leveraging its proprietary capabilities in rational and structure-based drug design.
Cockroach Labs, Inc. specializes in developing open-source database software, notably CockroachDB, which is a distributed SQL database tailored for modern cloud applications. Founded in 2015 and headquartered in New York, the company also has an office in Cambridge, Massachusetts. CockroachDB is designed to scale horizontally and can withstand various types of failures, including those at the disk, machine, rack, and datacenter levels, while maintaining minimal latency and no need for manual intervention. It supports strongly-consistent ACID transactions and offers an SQL API for data management. The software is suitable for diverse clients, ranging from startups to Fortune 500 companies, and is utilized for enterprise-grade disaster recovery services. CockroachDB combines the rich features of SQL with the scalability typically associated with NoSQL databases, enabling developers to innovate rapidly without compromising on consistency. The platform is trusted by major enterprises across various sectors, including finance, retail, and media.
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, ROME Therapeutics is pioneering the exploration of the repeatome, which consists of extensive regions of genetic material previously considered "junk DNA." The company has identified several drug targets and is actively advancing multiple discovery programs. To facilitate its research, ROME has assembled a team of experts across various disciplines, including oncology, immunology, virology, and machine learning, to harness this uncharted area of biology for therapeutic advancements.
Accent Therapeutics, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, focused on developing small molecule therapies for oncology through the innovative field of epitranscriptomics. Founded in 2017, the company explores post-transcriptional chemical modifications of RNA, which play a crucial role in regulating proteins essential for cellular growth and differentiation. By precisely targeting RNA-modifying proteins associated with cancer, Accent Therapeutics aims to translate advanced scientific research into effective treatments for patients, ultimately providing new therapeutic options in the fight against cancer.
Cerevance LLC is engaged in the development of therapeutics targeting specific proteins expressed selectively in brain cell types affected by neurological diseases. The company utilizes its proprietary NETSseq platform to profile distinct brain cell types, such as neurons and glial cells, in mature human brain tissue. This technology reveals transcriptional and epigenetic differences, facilitating the early detection and treatment of serious neurological and psychiatric disorders, including Alzheimer’s and Parkinson’s diseases. Founded in 2016, Cerevance is headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom. The company's focus is on advancing new medicines for central nervous system diseases by addressing the underlying mechanisms of neurodegeneration and related conditions.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
Merlin Labs is building an autonomous infrastructure for the sky above us, enabling goods, and eventually people, to fly without pilots.
SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.
Snyk Ltd. is a developer-focused cybersecurity company that provides a software-as-a-service platform designed to help organizations identify, fix, and monitor vulnerabilities in open-source dependencies and container images. The platform includes tools such as Snyk Code, which offers static application security testing, and container vulnerability management, which addresses vulnerabilities in Docker images. Snyk enables developers to scan their code for security issues directly within their code editors, providing alerts and remediation guidance based on an internal database of known vulnerabilities. The company also offers features for application security management, licensing compliance, and infrastructure as code security. Founded in 2015 and headquartered in London, Snyk has additional offices in Tel Aviv, Boston, and Ontario, and has established a strategic partnership with Rapid7, Inc.
Cockroach Labs, Inc. specializes in developing open-source database software, notably CockroachDB, which is a distributed SQL database tailored for modern cloud applications. Founded in 2015 and headquartered in New York, the company also has an office in Cambridge, Massachusetts. CockroachDB is designed to scale horizontally and can withstand various types of failures, including those at the disk, machine, rack, and datacenter levels, while maintaining minimal latency and no need for manual intervention. It supports strongly-consistent ACID transactions and offers an SQL API for data management. The software is suitable for diverse clients, ranging from startups to Fortune 500 companies, and is utilized for enterprise-grade disaster recovery services. CockroachDB combines the rich features of SQL with the scalability typically associated with NoSQL databases, enabling developers to innovate rapidly without compromising on consistency. The platform is trusted by major enterprises across various sectors, including finance, retail, and media.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.
Arrakis Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target ribonucleic acid (RNA) to treat a variety of diseases, including cancer and rare genetic disorders. The company employs a unique drug discovery platform that integrates advanced RNA bioinformatics and structural tools, allowing it to identify new RNA targets and create RNA-targeted small molecules (rSMs). Its proprietary pipeline consists of these rSMs aimed at genetically validated targets across multiple disease areas. Additionally, Arrakis offers SHAPEware, a software tool that assists in predicting RNA secondary structures and potential ligand-binding sites. Founded in 2015 and based in Waltham, Massachusetts, Arrakis Therapeutics aims to enhance therapeutic options for patients through its cutting-edge research and development efforts.
Lola Travel Company, Inc. specializes in corporate travel management through its AI-driven platform, Lola.com. Established in 2015 and based in Boston, Massachusetts, the company provides a user-friendly tool for booking flights and hotels, managing itineraries, and tracking travel expenses. Its services include individual travel profiles, digital travel receipts, and budget management features, catering to the needs of businesses and their employees. Lola.com offers a range of functionalities designed to simplify business travel, such as transparent spending reports, team destination sharing, and 24/7 agent support. The platform also includes a "book on behalf" feature, allowing executive assistants to manage travel arrangements efficiently.
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. This technology allows for targeted alterations of single bases in the genome without creating double-stranded breaks in DNA, representing a potential advancement in genetic therapies. The company's pipeline includes programs aimed at treating serious diseases such as sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, and pediatric acute myeloid leukemia, as well as conditions like alpha-1 antitrypsin deficiency and certain central nervous system disorders. Beam Therapeutics is committed to providing life-long cures through its various approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Founded in 2017, Beam continues to build collaborations to enhance its research and development efforts.
Lightmatter, Inc. is an artificial intelligence (AI) hardware company based in Boston, Massachusetts, that specializes in integrated optical technology to develop advanced computing processors. Founded in 2017, the company has created a silicon chip that utilizes light signals for processing, offering a new approach to AI computation. This technology accelerates critical operations in deep neural networks by employing programmable photonic elements alongside traditional transistors, enhancing the speed and efficiency of data processing while minimizing power consumption. Lightmatter's innovations aim to improve various AI applications, including image recognition and natural language processing, contributing to the advancement of next-generation AI-powered computing solutions.
Veo Robotics, Inc., founded in 2016 and based in Waltham, Massachusetts, specializes in developing robotics systems that enhance manufacturing processes. The company focuses on creating industrial automation products that allow high-performance robots to work collaboratively and safely alongside human workers. By integrating advanced computer vision, 3D sensing, and artificial intelligence, Veo Robotics' products aim to create more flexible, productive, and efficient manufacturing workcells. Their proprietary algorithms and distributed sensing technologies enable clients to improve productivity while reducing operating costs in both manufacturing and logistics environments.
Relay Therapeutics is a clinical-stage precision medicines company based in Cambridge, Massachusetts, focused on transforming the drug discovery process, particularly in targeted oncology. The company employs an innovative allosteric drug-discovery platform that integrates computational techniques with experimental methods to analyze protein motion and interactions. This approach aids in the development of therapies for complex diseases, including cancer. Relay's product candidates include RLY-1971, an oral small molecule inhibitor targeting SHP2, currently undergoing Phase 1 trials for advanced solid tumors; RLY-4008, a selective inhibitor of FGFR2 for tumors with specific oncogenic alterations; and RLY-PI3K1047, which targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery through its advanced platform and targeted treatment strategies.
RightHand Robotics, Inc. specializes in manufacturing robotic order-picking systems designed for various industrial applications, including e-commerce, food handling, and flexible manufacturing. The company offers innovative products such as the ReFlex SF, which features a 3D-printed palm equipped with servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor that enhances the robots' ability to grasp items gently and make adjustments to avoid errors. Their technology allows robots to automatically grasp a wide range of items from bins and cases, eliminating the need for extensive data-entry or parameter-tuning, thereby making the systems cost-effective and adaptable to the evolving needs of businesses. Founded in 2015, RightHand Robotics is headquartered in Cambridge, Massachusetts, with a sales and business development office located in Frankfurt, Germany.
Snyk Ltd. is a developer-focused cybersecurity company that provides a software-as-a-service platform designed to help organizations identify, fix, and monitor vulnerabilities in open-source dependencies and container images. The platform includes tools such as Snyk Code, which offers static application security testing, and container vulnerability management, which addresses vulnerabilities in Docker images. Snyk enables developers to scan their code for security issues directly within their code editors, providing alerts and remediation guidance based on an internal database of known vulnerabilities. The company also offers features for application security management, licensing compliance, and infrastructure as code security. Founded in 2015 and headquartered in London, Snyk has additional offices in Tel Aviv, Boston, and Ontario, and has established a strategic partnership with Rapid7, Inc.
Mabl Inc. offers an automated testing service that leverages machine learning to identify regressions and automatically fix broken tests. Founded in 2016 and based in Boston, Massachusetts, the company provides a scriptless testing solution as part of its software-as-a-service (SaaS) offerings. Mabl facilitates machine-driven regression testing and integrates seamlessly into the continuous integration and continuous delivery (CI/CD) development lifecycle. Its platform allows software development teams to create, execute, and maintain auto-healing tests efficiently, ensuring the rapid delivery of high-quality applications. Mabl serves a range of enterprise clients, including Johnson Controls, Liberty Mutual, Molina Healthcare, JetBlue, Dollar Shave Club, and Charles Schwab, who rely on its services for testing their critical applications.
Yesware, Inc. is a sales acceleration platform designed to assist sales professionals in enhancing their productivity and effectiveness. Founded in 2010 and headquartered in Boston, Massachusetts, with an additional office in San Francisco, Yesware provides a suite of tools that includes email tracking, scheduling, reminders, call placements, and performance monitoring. The platform allows users to see when prospects open emails and click on links, facilitating timely follow-ups. Its features also include customizable email templates and integration with various Customer Relationship Management (CRM) systems like Salesforce and Microsoft Dynamics, streamlining workflows and improving data quality. Yesware offers different pricing plans, including a free tier that allows users to track a limited number of emails monthly, as well as options for teams and enterprises. The company's focus is primarily on B2B sales professionals, providing them with insights and tools to help achieve their sales objectives.
SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.
Scandit AG, established in 2009 and headquartered in Zurich, Switzerland, specializes in mobile computer vision and augmented reality solutions, focusing on barcode scanning software. Its offerings include the Scandit Keyboard Wedge, which enables enterprise-grade barcode scanning on mobile devices, and the Barcode Scanner SDK, which allows for barcode scanning integration in web applications. The MatrixScan technology enhances the speed of barcode and text recognition, making it valuable for industries such as retail, logistics, manufacturing, healthcare, and government. Scandit's solutions are designed to improve operational efficiency by enabling mobile shopping, self-checkout, inventory management, and asset tracking, while also facilitating patient and medication tracking in healthcare settings. The company serves a diverse clientele, including well-known organizations like 7-Eleven, Carrefour, and Toyota, among others, and has additional offices in San Francisco, Boston, London, and Warsaw.
Tamr is an enterprise data unification company that is cost-effective, scalable, and accessible to any enterprise.
Following the success of initial research at MIT CSAIL, the Tamr team began building a commercial-grade solution designed to tackle the challenge of connecting and enriching diverse data at scale, quickly and cost effectively.
Launched in the spring of 2014 and backed by a series of investors, such as Google Ventures and New Enterprise Associates, Tamr is deployed in production at a variety organizations, including information services providers, pharmaceutical firms and retailers. Tamr, based in Cambridge, Massachusetts, was founded in 2013 by database industry veterans Andy Palmer, Mike Stonebraker and Ihab Ilyas with George Beskales, Daniel Bruckner and Alex Pagan.
Openbay, Inc. is an online marketplace that connects vehicle owners with automotive repair professionals, offering a range of services including air conditioning repairs, battery replacements, brake services, oil changes, and tire replacements. Founded in 2011 and based in Cambridge, Massachusetts, Openbay provides a software-as-a-service (SaaS) platform designed for the automotive care industry. This platform allows consumers to easily find, book, and pay for various automotive maintenance services from car dealerships, national service chains, independent shops, and mobile mechanics. Openbay aims to create a trusted and transparent marketplace for automotive services, helping users compare price quotes and transact conveniently. The company has gained recognition from major media outlets for its innovative approach to the automotive aftermarket and continues to be backed by notable investors.
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing therapies aimed at protecting, repairing, and restoring hearing. The company focuses on a range of hearing disorders, including those related to cancer treatments, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as tinnitus. It utilizes advanced techniques such as single-cell genomics, bioinformatics, and precision gene therapy technologies to enhance its understanding of inner ear pathology and to develop effective treatments. Decibel Therapeutics also offers expertise in drug delivery to the inner ear, imaging, and pharmacokinetic modeling, contributing to innovative therapeutic approaches for patients experiencing various forms of hearing loss. Founded in 2013 and based in Boston, Massachusetts, Decibel Therapeutics was previously known as Hearing, Inc. before rebranding in 2014.
FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.
SingleStore, Inc. is a provider of relational databases designed for both cloud and on-premises transactions and analytics. The company offers the SingleStore Managed Service, a cloud database-as-a-service that facilitates analytics on various cloud platforms, as well as SingleStore DB, a distributed SQL database suitable for operational analytics on bare metal and hybrid cloud environments. SingleStore's solutions include modernizing data platforms, securing government workloads, IoT analytics, and customer interaction management, serving diverse sectors such as financial services, media, energy, government, and retail. Founded in 2011 and headquartered in San Francisco, California, SingleStore also has offices in Seattle, Boston, Portland, Lisbon, and London. Previously known as MemSQL Inc., the company rebranded to SingleStore, Inc. in October 2020.
Celsius Therapeutics is a biotechnology company focused on developing innovative medicines to treat complex diseases, including autoimmunity and cancer. Founded in 2017 and based in Cambridge, Massachusetts, the company leverages advanced techniques such as single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. By systematically applying single-cell sequencing and analyzing extensive datasets with sophisticated algorithms, Celsius Therapeutics aims to discover critical biomarkers and precision therapies that enhance patient care and enable clinicians to identify genes that play a causal role in various conditions.
Relay Therapeutics is a clinical-stage precision medicines company based in Cambridge, Massachusetts, focused on transforming the drug discovery process, particularly in targeted oncology. The company employs an innovative allosteric drug-discovery platform that integrates computational techniques with experimental methods to analyze protein motion and interactions. This approach aids in the development of therapies for complex diseases, including cancer. Relay's product candidates include RLY-1971, an oral small molecule inhibitor targeting SHP2, currently undergoing Phase 1 trials for advanced solid tumors; RLY-4008, a selective inhibitor of FGFR2 for tumors with specific oncogenic alterations; and RLY-PI3K1047, which targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery through its advanced platform and targeted treatment strategies.
Obsidian Therapeutics develops innovative cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Founded in 2015 and based in Cambridge, Massachusetts, the company focuses on creating next-generation therapies that utilize pharmacologic operating systems to provide precise control over protein activity within cells. This technology allows for the development of adoptive cell therapies with advanced functionalities that can be managed by physicians using simple, safe, and orally active medications. By offering improved control over treatment, Obsidian Therapeutics aims to provide better outcomes for patients compared to existing cell therapy options.
Fractyl Health Inc. is a medical device company specializing in innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company's flagship product, Revita DMR, is a minimally invasive procedure that utilizes hydrothermal ablation to rejuvenate the lining of the duodenum, effectively addressing the underlying causes of these conditions. By focusing on transforming the treatment of metabolic diseases from merely managing symptoms to providing durable, disease-modifying solutions, Fractyl Health aims to significantly improve patient health outcomes. Founded in 2010 and based in Lexington, Massachusetts, the company is committed to developing curative therapies that lessen the burden on patients, healthcare providers, and payers.
Veo Robotics, Inc., founded in 2016 and based in Waltham, Massachusetts, specializes in developing robotics systems that enhance manufacturing processes. The company focuses on creating industrial automation products that allow high-performance robots to work collaboratively and safely alongside human workers. By integrating advanced computer vision, 3D sensing, and artificial intelligence, Veo Robotics' products aim to create more flexible, productive, and efficient manufacturing workcells. Their proprietary algorithms and distributed sensing technologies enable clients to improve productivity while reducing operating costs in both manufacturing and logistics environments.
LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated, genomically-enabled drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine aims to elucidate human biology and develop innovative therapeutics that target the underlying causes of serious diseases. By mining fungal biodiversity, the company seeks to create novel therapeutics designed to tackle previously intractable medical challenges, ultimately enhancing treatment options for healthcare providers.
Rodin Therapeutics is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapeutics for cognitive disorders through the application of epigenetic insights. Founded in 2013 with backing from Atlas Venture and Johnson & Johnson Development Corporation, the company leverages advanced structural biology capabilities and a team experienced in central nervous system (CNS) drug development. Rodin's innovative approach centers on the modulation of histone deacetylase (HDAC) complexes to restore synaptic function and promote neuronal health in degenerative brain diseases. This strategy aims to address significant unmet medical needs in the treatment of neurological disorders. As of November 2019, Rodin operates as a subsidiary of Alkermes Inc.
Toast, Inc. is a Boston-based company that specializes in developing a comprehensive point-of-sale and restaurant management platform tailored for the foodservice and hospitality industries. Founded in 2011, Toast provides cloud-based solutions that include online ordering, delivery tracking, tableside ordering, and labor management, all designed to streamline restaurant operations. The platform serves a diverse range of establishments, including restaurants, cafés, bars, and nightclubs, enabling them to enhance customer experiences and optimize business performance. By offering software subscription services, processing transaction fees, and providing financing through its Toast Capital division, Toast supports over 120,000 restaurant locations across the United States. The company stands out by processing a significant volume of financial transactions on its platform, reinforcing its commitment to delivering a robust and effective technology solution for restaurateurs.
Toast, Inc. is a Boston-based company that specializes in developing a comprehensive point-of-sale and restaurant management platform tailored for the foodservice and hospitality industries. Founded in 2011, Toast provides cloud-based solutions that include online ordering, delivery tracking, tableside ordering, and labor management, all designed to streamline restaurant operations. The platform serves a diverse range of establishments, including restaurants, cafés, bars, and nightclubs, enabling them to enhance customer experiences and optimize business performance. By offering software subscription services, processing transaction fees, and providing financing through its Toast Capital division, Toast supports over 120,000 restaurant locations across the United States. The company stands out by processing a significant volume of financial transactions on its platform, reinforcing its commitment to delivering a robust and effective technology solution for restaurateurs.
Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and discovering therapeutic antibodies for the treatment of solid tumors and hematological malignancies. The company's lead product candidate, CTX-471, is a fully human monoclonal antibody that acts as an agonist of CD137, currently undergoing Phase I clinical trials for patients who have had inadequate responses to existing PD-1/PD-L1 checkpoint inhibitors. In addition to CTX-471, Compass is advancing several preclinical assets, including CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, and CTX-8573, designed to engage natural killer (NK) cells against B cell maturation antigen, which is prevalent in multiple myeloma. Founded in 2014, Compass Therapeutics is headquartered in Cambridge, Massachusetts, and employs innovative platforms to enhance the efficacy of its antibody therapeutics.
Evelo Biosciences is a biotechnology company focused on developing oral biologics, specifically monoclonal microbials, for treating a range of inflammatory diseases and cancers. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company is advancing several candidates through various stages of clinical development. EDP1815, currently in a Phase 1b clinical study, aims to treat psoriasis and atopic dermatitis, while other candidates in pre-clinical stages target conditions such as psoriatic arthritis, asthma, and neuro-inflammatory diseases. Additionally, EDP1503 is undergoing Phase 1/2 trials for colorectal cancer and other malignancies. By utilizing naturally occurring monoclonal microbials, Evelo seeks to revolutionize drug discovery and development, offering a new approach to modulating systemic immunology and biology through oral delivery. This innovative platform has the potential to enhance the efficiency and effectiveness of treatments across various health conditions.
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing therapies aimed at protecting, repairing, and restoring hearing. The company focuses on a range of hearing disorders, including those related to cancer treatments, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as tinnitus. It utilizes advanced techniques such as single-cell genomics, bioinformatics, and precision gene therapy technologies to enhance its understanding of inner ear pathology and to develop effective treatments. Decibel Therapeutics also offers expertise in drug delivery to the inner ear, imaging, and pharmacokinetic modeling, contributing to innovative therapeutic approaches for patients experiencing various forms of hearing loss. Founded in 2013 and based in Boston, Massachusetts, Decibel Therapeutics was previously known as Hearing, Inc. before rebranding in 2014.
LevelUp is focused on creating advanced mobile experiences for over 200 brands across the United States, facilitating customer engagement and sales growth through a comprehensive platform. This platform includes a variety of features such as mobile rewards, payments, online ordering, customer relationship management, and loyalty programs. By consolidating data from in-store and online transactions, LevelUp enables merchants to design and execute targeted marketing campaigns that aim to boost customer spending and frequency. The company has established strategic partnerships with major organizations, providing restaurants access to a broader customer base beyond their own applications. LevelUp distinguishes itself by developing a mobile payment network that positions businesses to adapt to future changes in the mobile landscape.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for genetically defined diseases with high unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a progressive muscle-wasting disorder. Another key candidate, FTX-6058, aims to increase fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia. In addition to these programs, Fulcrum is exploring drug targets for other conditions such as Duchenne muscular dystrophy, Friedreich ataxia, myotonic dystrophy 1, and various neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma and MyoKardia to advance research and develop targeted therapies for pulmonary diseases and genetic cardiomyopathies, respectively. Founded in 2015, Fulcrum Therapeutics is committed to improving the lives of patients facing significant health challenges.
Cockroach Labs, Inc. specializes in developing open-source database software, notably CockroachDB, which is a distributed SQL database tailored for modern cloud applications. Founded in 2015 and headquartered in New York, the company also has an office in Cambridge, Massachusetts. CockroachDB is designed to scale horizontally and can withstand various types of failures, including those at the disk, machine, rack, and datacenter levels, while maintaining minimal latency and no need for manual intervention. It supports strongly-consistent ACID transactions and offers an SQL API for data management. The software is suitable for diverse clients, ranging from startups to Fortune 500 companies, and is utilized for enterprise-grade disaster recovery services. CockroachDB combines the rich features of SQL with the scalability typically associated with NoSQL databases, enabling developers to innovate rapidly without compromising on consistency. The platform is trusted by major enterprises across various sectors, including finance, retail, and media.
Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.
As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
ZappRx, Inc. is a digital health company based in Boston, Massachusetts, that specializes in a cloud-based platform designed to streamline the management of specialty medications. Founded in 2012, the company provides a secure online environment where healthcare providers, specialty pharmacies, and biopharma companies can collaborate efficiently. Its platform automates the prescription and prior authorization processes, facilitating communication among patients, physicians, and pharmacists while reducing reliance on traditional methods such as faxes and phone calls. By consolidating essential information related to specialty prescribing—including pharmacy details, payer requirements, and clinical history—the platform enhances the efficiency and transparency of healthcare delivery, particularly in the fields of pulmonary, cardiology, and gastroenterology. ZappRx operates as a subsidiary of Allscripts Healthcare Solutions, Inc. as of June 2019.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.